Literature DB >> 16331785

Outcome measures for acute and chronic gout.

H Ralph Schumacher1, Lawrence N Edwards, Fernando Perez-Ruiz, Michael Becker, Lan X Chen, Daniel E Furst, Nancy Joseph-Ridge, Naomi Schlesinger, Zeb Horowitz, Kenneth Saag, Judith A Boice, Hisashi Yamanaka.   

Abstract

Gout provides some unique challenges in classification and measurement of outcomes. Our aim was to evaluate criteria for classification and to develop and validate optimal instruments to measure outcomes for acute and chronic gout. A planning committee and interested attendees met to propose classification criteria and domains for outcomes. Seven of the current American Rheumatism Association preliminary criteria for classification were proposed as the best current criteria for acute gouty arthritis, pending further studies. The presence of gout is best established by crystal identification, although this technique has limitations. Five domains for acute gout outcomes and 9 for chronic gout were identified along with proposed instruments for testing and validation. The unique problems of gout evaluation can and will be addressed.

Entities:  

Mesh:

Year:  2005        PMID: 16331785

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Oral colchicine (colcrys®) in the treatment and prophylaxis of gout†: profile report.

Authors:  Lily P H Yang
Journal:  Drugs Aging       Date:  2010-10-01       Impact factor: 3.923

Review 2.  Why is gout so poorly managed?

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

3.  Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.

Authors:  Axel Finckh; Geraldine M Mc Carthy; Anne Madigan; Daniel Van Linthoudt; Marcel Weber; David Neto; Georges Rappoport; Sandra Blumhardt; Diego Kyburz; Pierre-Andre Guerne
Journal:  Arthritis Res Ther       Date:  2014-10-15       Impact factor: 5.156

Review 4.  Outcome measures in acute gout: a systematic literature review.

Authors:  Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

Review 5.  Oral colchicine (Colcrys): in the treatment and prophylaxis of gout.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

6.  Experiences of gout-related disability from the patients' perspective: a mixed methods study.

Authors:  Peter M ten Klooster; Harald E Vonkeman; Martijn A H Oude Voshaar; Christina Bode; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-08       Impact factor: 2.980

7.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

Review 8.  Imaging of gout: findings and utility.

Authors:  Fernando Perez-Ruiz; Nicola Dalbeth; Aranzazu Urresola; Eugenio de Miguel; Naomi Schlesinger
Journal:  Arthritis Res Ther       Date:  2009-06-17       Impact factor: 5.156

Review 9.  Febuxostat for treating chronic gout.

Authors:  Jean H Tayar; Maria Angeles Lopez-Olivo; Maria E Suarez-Almazor
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Systemic corticosteroids for acute gout.

Authors:  H J E M Janssens; P L B J Lucassen; F A Van de Laar; M Janssen; E H Van de Lisdonk
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.